HMGA2 是 IDH 突变型星形细胞瘤的独立预后指标和潜在治疗靶点
研究利用 CGGA(96 例)、CGGA2019(150 例)和 TCGA(222 例)的 RNA 测序数据,比较复发与原发 IDH 突变型星形细胞瘤的差异表达基因,发现 HMGA2 在复发肿瘤中高表达,与细胞迁移侵袭及细胞外基质相关,是独立不良预后因素,可能作为预后生物标志物和治疗靶点。
要点
- HMGA2 在复发 IDH 突变型星形细胞瘤中较原发肿瘤高表达。
- HMGA2 高表达患者更可能为高级别胶质瘤和 MGMTp 甲基化组。
- HMGA2 是 IDH 突变型星形细胞瘤不良预后的独立因素。
核心结论
- HMGA2 在复发 IDH 突变型星形细胞瘤中高表达,高表达与细胞迁移和侵袭能力增强相关,可能作为不良预后生物标志物和有效治疗靶点。
研究设计与样本
- 研究收集 CGGA 数据库 96 例、CGGA2019 数据库 150 例和 TCGA 数据库 222 例 IDH 突变型星形细胞瘤患者的 RNA 测序数据。
主要发现
- 复发 IDH 突变型星形细胞瘤患者中 HMGA2 表达高于原发患者。
- HMGA2 高表达患者更可能为高级别胶质瘤和 MGMTp 甲基化组。
- 功能富集和相关分析显示 HMGA2 与细胞外基质含量及细胞迁移侵袭能力密切相关。
- HMGA2 是 IDH 突变型星形细胞瘤不良预后的独立因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although IDH-mutant astrocytomas exhibit more favorable survival outcomes compared to their IDH-wildtype counterparts, therapeutic failure in recurrent cases persists as a significant clinical challenge. The objective of this study is to identify genes associated with recurrence in IDH-mutant astrocytoma and to elucidate their expression pattern, biological functions, and prognostic value. METHODS: RNA-sequencing data of patients with IDH-mutant astrocytoma were collected from 96 cases in the Chinese Glioma Genome Atlas (CGGA) database, 150 cases in CGGA2019 and 222 cases in The Cancer Genome Atlas (TCGA). Differentially expressed genes (DEGs) were identified using unpaired t-tests between recurrent and primary IDH-mutant astrocytoma. GO and KEGG analyses were performed to analyze these DEGs. Pearson correlation analysis was employed to assess the correlation between High mobility group AT-hook 2 (HMGA2) and genes associated with cell invasion and extracellular matrix components. Kaplan-Meier analyses and univariate and multivariate Cox regression analyses were conducted to assess the prognosis. RESULTS: HMGA2 was highly expressed in patients with recurrent IDH-mutant astrocytoma in comparison to those with primary IDH-mutant astrocytoma. Patients with higher HMGA2 expression are more likely to have high-grade gliomas and to be in the O6-methylguanine-DNA methyltransferase promoter (MGMTp) methylation group. Functional enrichment and correlation analyses revealed that HMGA2 is closely related to extracellular matrix content and cell migration and invasion ability. HMGA2 is an independent prognostic factor associated with poor prognosis in patients with IDH-mutant astrocytoma. CONCLUSIONS: HMGA2 was highly expressed in recurrent IDH-mutant astrocytoma, with higher expression levels associated with increased cell migration and invasion abilities. HMGA2 has the potential to serve as a biomarker for poor prognosis and may represent an effective therapeutic target in the treatment of IDH-mutant astrocytoma.
引用
- Wan L, Liu Z, Li S, et al. HMGA2 is an independent prognostic indicator and a potential therapeutic target for IDH-mutant astrocytoma. Acta Neurochir (Wien). 2025. PMID: 40379848. doi:10.1007/s00701-025-06548-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。